GlassScriptPhysician profile
Michael Y Li
NPI 1770547630
$14,288.56
in general payments reported to CMS, 2019-2025
39 companies · $3,575 in 2025
The $3,575 reported for 2025 was more than what 88% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,672 · 2020: $3,007 · 2021: $1,163 · 2022: $1,231 · 2023: $1,440 · 2024: $2,200 · 2025: $3,575.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,117 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,116.65 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $2,857.51 | 2024-2025 | Aurora Ev-Icd Mri Surescan, Azure Xt Dr Mri Surescan, Micra |
| Gilead Sciences, INC. | $2,827.52 | 2019-2025 | |
| Redhill Biopharma INC. | $2,416.52 | 2020-2021 | |
| Abbvie INC. | $1,396.44 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $872.11 | 2022-2024 | Austedo Xr, Uzedy, Austedo |
| Neurocrine Biosciences, INC. | $538.43 | 2021-2025 | Ingrezza |
| Intercept Pharmaceuticals, INC. | $318.36 | 2019-2025 | Ocaliva |
| Janssen Biotech, INC. | $287.20 | 2021-2025 | Tremfya, Simponi Aria, Remicade |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $265.20 | 2022-2023 | |
| Phathom Pharmaceuticals, INC. | $212.45 | 2024-2025 | Voquezna |
| Amgen INC. | $202.75 | 2024-2025 | Uplizna |
| Intra-Sana Laboratories | $191.27 | 2022-2025 | Glycate, Reltone 200 Mg, Reltone 400 Mg |
| Celgene Corporation | $158.89 | 2021-2024 | Zeposia |
| Novo Nordisk INC | $145.44 | 2025 | Wegovy |
| Alkermes, INC. | $130.00 | 2025 | Lybalvi |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Li listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.